geo_老虎社区_美港股上老虎

enyj
2021-06-16

geo

Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally<blockquote>Orphazyme主要投资者Sunstone在散户投资者推动的反弹后减持股份</blockquote>

Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the

Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally<blockquote>Orphazyme主要投资者Sunstone在散户投资者推动的反弹后减持股份</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":169593843,"tweetId":"169593843","gmtCreate":1623841457482,"gmtModify":1634027281196,"author":{"id":3586783123137653,"idStr":"3586783123137653","authorId":3586783123137653,"authorIdStr":"3586783123137653","name":"enyj","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>geo</p></body></html>","htmlText":"<html><head></head><body><p>geo</p></body></html>","text":"geo","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/169593843","repostId":1150256789,"repostType":4,"repost":{"id":"1150256789","kind":"news","pubTimestamp":1623833619,"share":"https://www.laohu8.com/m/news/1150256789?lang=zh_CN&edition=full","pubTime":"2021-06-16 16:53","market":"us","language":"en","title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally<blockquote>Orphazyme主要投资者Sunstone在散户投资者推动的反弹后减持股份</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","media":"benzinga","summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","content":"<p><div> Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares. What Happened...</p><p><blockquote><div>Orphazyme A/S的主要股东Sunstone Life Science Ventures在散户投资者推动的丹麦生物制药公司股价上涨后减持了其股份。发生了什么...</div></blockquote></p><p>  <a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">网页连接</a></blockquote></p><p></p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally<blockquote>Orphazyme主要投资者Sunstone在散户投资者推动的反弹后减持股份</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally<blockquote>Orphazyme主要投资者Sunstone在散户投资者推动的反弹后减持股份</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">benzinga</strong><span class=\"h-time small\">2021-06-16 16:53</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares. What Happened...</p><p><blockquote><div>Orphazyme A/S的主要股东Sunstone Life Science Ventures在散户投资者推动的丹麦生物制药公司股价上涨后减持了其股份。发生了什么...</div></blockquote></p><p>  <a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">benzinga</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150256789","content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","news_type":1,"symbols_score_info":{"ORPH":0.9}},"isVote":1,"tweetType":1,"viewCount":3025,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}